The University of Kansas Hospital is one of 16 sites that will be allowed to dispense Yescarta, a new gene therapy treatment for non-Hodgkin’s lymphoma. It’s the second treatment approved by the U.S. Food and Drug Administration in which a patient’s own immune cells are extracted, genetically engineered into cancer-killers, and then reinfused into the body.
The University of Kansas Hospital is one of 16 sites that will be allowed to dispense Yescarta, a new gene therapy treatment for non-Hodgkin’s lymphoma. It’s the second treatment approved by the U.S. Food and Drug Administration in which a patient’s own immune cells are extracted, genetically engineered into cancer-killers, and then reinfused into the body. File photo by JOHN SLEEZER
The University of Kansas Hospital is one of 16 sites that will be allowed to dispense Yescarta, a new gene therapy treatment for non-Hodgkin’s lymphoma. It’s the second treatment approved by the U.S. Food and Drug Administration in which a patient’s own immune cells are extracted, genetically engineered into cancer-killers, and then reinfused into the body. File photo by JOHN SLEEZER

‘Revolution in cancer medicine’: KU joins fight with approval of this therapy

October 20, 2017 02:29 PM